Granisetron Hameln (Granisetron Hydrochloride)

Granisetron Hameln is indicated for the prevention and treatment of nausea and vomiting in specific clinical situations.

• Chemotherapy‑induced nausea and vomiting (CINV).
• Post‑operative nausea and vomiting (PONV).
• Nausea associated with radiotherapy.
• Antiemetic prophylaxis for patients receiving highly emetogenic chemotherapy.
• Nausea related to anesthesia recovery.
• Nausea in patients undergoing bone marrow transplantation.

The safety profile of Granisetron Hameln includes both frequent, mild reactions and rare, more serious events.

Common

• Headache, typically mild to moderate.
• Constipation or reduced bowel movements.
• Fatigue or feeling of tiredness.
• Dizziness or light‑headed sensation.
• Pain, redness, or swelling at the injection site.

Serious

• Anaphylactic reaction, including rash, swelling, or breathing difficulty.
• Cardiac arrhythmias, such as irregular heartbeat.
• Prolongation of the QT interval on electrocardiogram.
• Serotonin syndrome when used with other serotonergic drugs.

Before prescribing Granisetron Hameln, clinicians should consider several precautionary factors to ensure safe use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with known cardiac conduction disorders or prolonged QT interval.
• Evaluate renal and hepatic function, as dose adjustments may be needed in severe impairment.
• Monitor for signs of serotonin syndrome if the patient is receiving serotonergic medications.
• Consider pregnancy and breastfeeding status; data are limited, so weigh potential benefits against risks.
• Avoid use in patients with severe electrolyte disturbances that predispose to cardiac arrhythmias.

Granisetron Hameln can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Other 5‑HT3 receptor antagonists, as additive antiemetic effect may increase risk of cardiac effects.
• Drugs known to prolong QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics).

Use with caution

• Serotonergic agents such as SSRIs, SNRIs, tramadol, or linezolid, due to risk of serotonin syndrome.
• CYP3A4 inhibitors or inducers, which may alter granisetron plasma levels.
• Electrolyte‑altering diuretics that could affect cardiac conduction.